- Previous Close
86.42 - Open
86.12 - Bid 87.01 x 1100
- Ask 88.23 x 1000
- Day's Range
85.50 - 88.71 - 52 Week Range
49.15 - 88.71 - Volume
5,268,361 - Avg. Volume
5,500,635 - Market Cap (intraday)
129.695B - Beta (5Y Monthly) 0.80
- PE Ratio (TTM)
71.60 - EPS (TTM)
1.23 - Earnings Date Oct 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
89.83
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
www.bostonscientific.comRecent News: BSX
View MorePerformance Overview: BSX
Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BSX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BSX
View MoreValuation Measures
Market Cap
127.26B
Enterprise Value
135.29B
Trailing P/E
70.26
Forward P/E
31.65
PEG Ratio (5yr expected)
2.13
Price/Sales (ttm)
8.40
Price/Book (mrq)
6.25
Enterprise Value/Revenue
8.88
Enterprise Value/EBITDA
37.10
Financial Highlights
Profitability and Income Statement
Profit Margin
12.00%
Return on Assets (ttm)
4.81%
Return on Equity (ttm)
9.32%
Revenue (ttm)
15.23B
Net Income Avi to Common (ttm)
1.83B
Diluted EPS (ttm)
1.23
Balance Sheet and Cash Flow
Total Cash (mrq)
2.91B
Total Debt/Equity (mrq)
53.06%
Levered Free Cash Flow (ttm)
1.61B
Research Analysis: BSX
View MoreCompany Insights: BSX
BSX does not have Company Insights
Research Reports: BSX
View MoreLarge Cap US Pick List - August 2024
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.
Raising EPS estimates for 2024 and 2025
Based in Marlborough, Massachusetts, Boston Scientific is a developer, manufacturer, and marketer of medical devices used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, oncology, endoscopy, urology, gynecology, and neuromodulation. The company is a component of the S&P 500.
RatingPrice TargetEarnings news continues as the big driver today. All the action is
Earnings news continues as the big driver today. All the action is mostly in individual stocks reacting to whether last quarter was positive or negative, plus any intel on outlook. The major indices are not showing any big moves, but at midday the Nasdaq is showing signs of weakening. The 2-day Fed meeting starts today with a rate decision coming tomorrow and more importantly, Chairman Powell's press conference that follows.
Boston Scientific Earnings: Strong Farapulse Adoption and Pipeline Prospects Lead to Higher FVE
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
RatingPrice Target